U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06839118) titled 'Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache' on Feb. 03.
Brief Summary: The study is an investigator-initiated randomized, placebo-controlled, double-blind, parallelgroup trial. Eighty subjects with PTH will be included and randomized 1:1 for treatment with BTX-A or placebo (isotonic saline). The study comprises a 4-week baseline phase before injection of either active drug or placebo followed by a 12-week evaluation period. Treatment will be double-blind, and subjects will only receive one treatment cycle. Endpoints will be assessed in the evaluation period (weeks 5 to 8) compared to baseline (w...